BAY 2965501, another DGKζ-selective inhibitor, showed in vitro activity by increasing natural killer (NK)- and T-cell-mediated tumor cell killing and enhancing IL-2-induced NK cell activation. This evidence concerns the gene DGKZ and neoplasm.